CITY-OF-TAMPERE
15.5.2019 14:11:10 CEST | Business Wire | Press release
An international ideas competition started off on 15 May 2019 in Viinikanlahti, a highly exciting area close to Tampere city centre. Competitors get to design a housing area of over 3,000 residents on the shores of Lake Pyhäjärvi, as well as a leisure time environment for the locals and tourists. With a population of roughly 370,000, the sustainably growing Tampere is the largest inland city in the Nordic Countries and, together with the neighbouring municipalities, forms the second-largest urban area in Finland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190515005494/en/
The aim of the ideas competition, which is open to all, is to create a new and ecologically sustainable city district that boasts high-quality architecture and meets the needs of the 21st century. The competition task is exceptionally interesting: the unique Viinikanlahti area has the most beautiful lake views in the centre of Tampere, but also involves environmental challenges. The size of the competition area (land and water) is roughly 0.4 hectares. The wastewater treatment plant currently operating in the area will be moved elsewhere. After the competition, both a master plan and a local detailed plan will be prepared for the area. The environment will be cleaned and the new city district constructed in phases between 2024-2035.
The international ideas competition is organised mainly digitally, and is expected to attract plenty of participants from Finland and abroad. A total of 165,000–345,000 euros will be awarded in prizes in the two-phased competition, the winner of which will be selected in April 2020. The competition is organised by the City of Tampere in cooperation with the Finnish Association of Architects (SAFA) and the Association of Finnish Landscape Architects (MARK).
The economy of the City of Tampere focuses on services and high-technology. Innovative, digital, and sustainable smart city solutions are being created in the region together with companies, research institutions, municipalities, and residents. The population of Tampere is increasing by over 3,000 residents a year. New construction is constantly being implemented in the area, and new ecological and low-emission solutions are needed to enable the carbon-neutral and sustainable growth of the city in accordance with its strategy.
Competition website:
Further information:
YouTube: @tampereenkaupunki
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005494/en/
Contact:
Executive Director, Growth, Innovation and Competitiveness Services Teppo Rantanen +358 400235442 teppo.t.rantanen@tampere.fi Project Director Tero Tenhunen +358 505402860 tero.tenhunen@tampere.fi Project Development Manager Minna Seppänen +358 401509857 minna.seppanen@tampere.fi
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom